Match!
Alain Luxembourg
Merck & Co.
60Publications
20H-index
1,597Citations
Publications 60
Newest
#1Anna R. GiulianoH-Index: 65
#2Elmar A. Joura (Medical University of Vienna)H-Index: 32
Last.Robert J. Kurman (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 107
view all 15 authors...
Abstract Objective Nine-valent human papillomavirus (9vHPV) vaccine efficacy against disease and cervical surgeries related to all nine vaccine components was assessed compared with a historic placebo population. This was not assessed in the 9vHPV vaccine efficacy trial since the trial was quadrivalent HPV (qHPV) vaccine-controlled, efficacy was measured for the five HPV types covered only by 9vHPV vaccine (HPV31/33/45/52/58), but not the four types covered by both vaccines (HPV6/11/16/18). Meth...
#1Ana María GuevaraH-Index: 2
#2Eugenio Suarez (University of Chile)H-Index: 4
Last.Amita Joshi (MSD: Merck & Co.)H-Index: 4
view all 10 authors...
ABSTRACTBackground: This exploratory analysis was conducted to characterize the level of HPV types 6/11 antibodies in peripartum maternal blood and in cord blood of infants born to women who received 9-valent HPV (9vHPV) vaccine or quadrivalent HPV (qHPV) vaccine in a pivotal efficacy study (V503-001, NCT 00543543).Methods: A total of 21 mother-infant pairs had evaluable HPV 6/11 results available for analysis. HPV6/11 antibodies were assessed using competitive Luminex immunoassay. The distribut...
#1Suzanne M. Garland (UVA: University of Virginia)H-Index: 61
#2Elmar A. Joura (UVA: University of Virginia)H-Index: 32
Last.Mauricio Hernandez-Avila (UVA: University of Virginia)H-Index: 3
view all 31 authors...
OBJECTIVE:To estimate the proportion of vulvar and vaginal low-grade and high-grade squamous intraepithelial lesions (LSILs and HSILs) in females 15–26 years of age attributable to 14 human papillomavirus (HPV) genotypes (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59).METHODS:A post hoc anal
#1Evan R. Meyers (Duke University)H-Index: 1
#2Alain Luxembourg (MSD: Merck & Co.)H-Index: 20
Last.Christine Velicer (MSD: Merck & Co.)H-Index: 19
view all 4 authors...
5530Background: Few studies have reported the burden of Pap abnormalities associated with the specific HPV types targeted by HPV vaccines. The purpose of this analysis is to estimate prevalence of ...
#2Anna R. GiulianoH-Index: 65
Last.Alain Luxembourg (MSD: Merck & Co.)H-Index: 20
view all 4 authors...
1553Background: The quadrivalent human papillomavirus (qHPV) vaccine prevented HPV6/11/16/18-related persistent infection and external genital lesions in young men in an international, randomized, placebo-controlled pivotal efficacy study. We report the end-of-study analysis of a long-term follow up (LTFU) extension study that assessed the effectiveness and immunogenicity of the qHPV vaccine through 10 years after the first dose. Methods: In the 3-year base study, young men (16-26 years old) wer...
#1Edson Duarte Moreira Junior (Obras Sociais Irmã Dulce)
#2Anna R. GiulianoH-Index: 65
Last.Misoo C. Ellison (MSD: Merck & Co.)H-Index: 4
view all 14 authors...
aCentro de Pesquisa Clinica, Associacao Obras Sociais Irma Dulce and Oswaldo Cruz Foundation, Brazilian Ministry of Health, Salvador, Bahia, Brazil; bDepartment of Cancer Epidemiology, Center for Infection Research (CIRC), Moffitt Cancer Center, Tampa, Florida, USA; cCenter for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; dDepartment of Clinical Science, University of Bergen/Womens Clinic, Haukeland University Hospital, Bergen, Nor...
#1Ángela María Ruiz Sternberg (Del Rosario University)H-Index: 5
#2Edson D. Moreira (Obras Sociais Irmã Dulce)H-Index: 9
Last.Alejandro VictoriaH-Index: 1
view all 24 authors...
Moreira Junior, Edson Duarte. Associacao Obras Sociais Irma Dulce / Fundacao Oswaldo Cruz. Centro de Pesquisas Goncalo Moniz. Salvador, BA, Brasil. a Clinical Research Group, Universidad del Rosario, Bogota, Colombia b Associacao Obras Sociais Irma Dulce and Oswaldo Cruz Foundation, Brazilian Ministry of Health, Bahia, Brazil c Foundation Clinical Research Center CIC, Medellin, Colombia d Research Center on Public Health, National Institute of Public Health, Cuernavaca, Morelos, Mexico e Via Lib...
#1Alain Luxembourg (MSD: Merck & Co.)H-Index: 20
#2Erin Moeller (MSD: Merck & Co.)H-Index: 7
ABSTRACTIntroduction: The 9-valent human papillomavirus (9vHPV) vaccine covers the same HPV types (6/11/16/18) as the quadrivalent HPV (qHPV) vaccine and 5 additional cancer-causing types (31/33/45/52/58). Epidemiological studies indicate that the 9vHPV vaccine could prevent approximately 90% of cervical cancers, 70–85% of high-grade cervical dysplasia (precancers), 85–95% of HPV-related vulvar, vaginal, and anal cancers, and 90% of genital warts.Areas covered: Study design features and key find...
#1Warner K. Huh (UAB: University of Alabama at Birmingham)H-Index: 43
#2Elmar A. Joura (Medical University of Vienna)H-Index: 32
Last.Angelica Lindén Hirschberg (Karolinska University Hospital)H-Index: 34
view all 28 authors...
Summary Background Primary analyses of a study in young women aged 16–26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections and disease related to HPV 31, 33, 45, 52, and 58, and non-inferior HPV 6, 11, 16, and 18 antibody responses when compared with quadrivalent HPV (qHPV; HPV 6, 11, 16, and 18) vaccine. We aimed to report efficacy of the 9vHPV vaccine for up to 6 years following first administration and a...
123456